Caribou Biosciences, Inc. announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-012, an allogeneic anti-C-type lectin- like molecule-1 (anti-CLL-1) CAR-T cell therapy. CB-012 will be evaluated in the multicenter, open-label, AMpLify Phase 1 clinical trial for patients with relapsed or refractory acute myeloid leukemia (r/r AML).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.085 USD | -3.70% | -27.43% | -63.53% |
Jun. 04 | US Equities Markets Close Mixed Monday as US Manufacturing Contracts | MT |
Jun. 04 | HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.53% | 196M | |
+52.15% | 55.7B | |
+41.08% | 39.91B | |
-5.75% | 39.57B | |
-5.56% | 28.16B | |
+16.10% | 26.3B | |
-20.06% | 18.94B | |
+32.39% | 12.17B | |
+26.45% | 12.12B | |
+1.85% | 12.12B |
- Stock Market
- Equities
- CRBU Stock
- News Caribou Biosciences, Inc.
- Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia